Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 13, 2026
TickeronGET DAILY SIGNALS
TCRT and ZBAO: Biotech Turnaround Meets InsurTech with a Bitcoin Strategy

TCRT and ZBAO: Biotech Turnaround Meets InsurTech with a Bitcoin Strategy

Key Takeaways

  • TCRT (Alaunos Therapeutics) is a biotechnology company that recently completed a transformative acquisition of Velaris Therapeutics alongside a roughly $350 million private placement, refocusing its pipeline toward pulmonary and metabolic programs.
  • ZBAO (Zhibao Technology) is a Shanghai-based digital insurance brokerage that has adopted a corporate Bitcoin (BTC) treasury strategy while working to regain Nasdaq listing compliance.
  • The two names sit at opposite ends of the risk spectrum: TCRT is a pre-revenue, clinical-stage biotech, while ZBAO operates a revenue-generating insurance technology (InsurTech) business.
  • TCRT shares have surged in recent weeks on the merger and financing announcement, whereas ZBAO has fallen sharply year-to-date and recently pursued a 1-for-50 reverse stock split.
  • Both companies have faced Nasdaq compliance challenges, underscoring elevated volatility and execution risk in each name.

Setting the Stage for These Two Names

This comparison looks at two small-cap Nasdaq-listed companies each undergoing significant shifts. TCRT, Alaunos Therapeutics, is a biotechnology firm executing what amounts to a reverse-merger transaction paired with a sizable capital raise. ZBAO, Zhibao Technology, is a Chinese digital insurance broker that has added a Bitcoin treasury component to its operations. The setup is particularly relevant for traders focused on momentum plays, turnaround stories, and relative performance in volatile, low-float names.

TCRT: From TCR-T Therapies to a Pulmonary Pipeline

Alaunos Therapeutics, previously known as Ziopharm Oncology, has operated as a clinical- and preclinical-stage biotech. Its earlier work centered on T-cell receptor therapies for solid tumors via the Sleeping Beauty platform, alongside a small-molecule program in obesity and metabolic disease. The recent stock-for-stock acquisition of Velaris Therapeutics, a private company with pulmonary drug programs, combined with an approximately $350 million private placement led by Fairmount and other institutions, effectively redirects the company. The move channels resources toward Velaris’s pipeline while preserving some focus on the obesity assets. The funding is projected to support operations through 2029 and advance candidates to IND filings and early proof-of-concept data. Shares reacted positively to the announcement, though the company remains pre-revenue and success will hinge on clinical delivery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ZBAO: InsurTech Growth Layered with a Bitcoin Treasury

Zhibao Technology runs a digital insurance brokerage in China under a 2B2C model, partnering with distribution channels and providing proprietary digital solutions plus managing general underwriter services. Latest reported results showed revenue up roughly 41% year over year from channel expansion, though higher operating expenses kept profitability in check. Attention has also turned to the company’s corporate Bitcoin holdings, which reached approximately 2,380 BTC following a funded placement. At the same time, the stock has declined sharply year-to-date, traded below the $1.00 bid-price threshold, and prompted a 1-for-50 reverse split to address Nasdaq requirements. Operating losses, leverage, and the unproven nature of the treasury strategy have pressured sentiment even as the core brokerage business shows top-line progress. From what I see, the combination of business fundamentals and crypto exposure creates a distinct risk profile.

Head-to-Head: Business Models and Market Paths

The clearest distinction lies in the underlying models. TCRT is a pre-revenue biotech whose value rests on future clinical milestones and successful integration of the newly acquired assets. The capital raise extends the runway but introduces dilution and shifts influence to new investors. ZBAO, on the other hand, generates revenue yet has not consistently converted growth into profits, while its Bitcoin treasury adds crypto-market sensitivity separate from insurance operations. Momentum has also diverged: TCRT rallied on a defined catalyst, whereas ZBAO has trended lower and needed the reverse split to maintain listing status. Risk factors differ as well—TCRT carries clinical, regulatory, and integration exposure, while ZBAO faces compliance hurdles, thin margins, and digital-asset volatility. Sector exposure is entirely separate, so the two names are unlikely to move in tandem and serve different purposes in a broader strategy. I’m watching this closely because the divergence highlights how catalyst-driven names can separate from those navigating ongoing compliance and profitability questions.

AI Assessment and Positioning

From a probability-weighted perspective, current factors appear to favor TCRT more than ZBAO. The former benefits from a clear transformational catalyst, extended funding visibility, and an upward trend shift after the acquisition news. The latter shows weaker price momentum, lingering listing concerns, and a treasury approach whose longer-term impact is still untested. Both remain highly volatile, and fresh developments could alter the relative standing quickly.

Exploring Tickeron AI Trading Bots

In my own research process, I often turn to Tickeron’s AI Trading Bots to test how automated strategies align with names like these. The platform hosts a wide range of bots, each with defined styles, timeframes, and performance metrics across thousands of tickers. By reviewing the current set of featured bots, it becomes easier to identify approaches that match the present market environment and the specific characteristics of volatile small-caps. This step adds a data layer that complements traditional fundamental review. AI Trading Bots

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TCRT, ZBAO

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


TCRT in +7.50% Uptrend, rising for three consecutive days on November 18, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TCRT advanced for three days, in 182 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 72 cases where TCRT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

TCRT moved above its 50-day moving average on November 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for TCRT moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRT as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TCRT turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 10-day moving average for TCRT crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TCRT entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.780) is normal, around the industry mean (3.596). P/E Ratio (-0.994) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a cancer treatment company

Industry Biotechnology

Industry
Biotechnology
Address
501 East Las Olas Boulevard
Phone
+1 346 355-4099
Employees
1
Web
https://www.alaunos.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.